Treatment of severe autoimmune thrombocytopenic purpura [8] (multiple letters)

Lancet

Volumn 359, Issue 9325, 2002, Pages 2279-2280

  Carradice, Duncan ^a   Balaraman, Rama ^b   Bierling, P ^c   Godeau, B ^c  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF MISSOURI   (United States)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; ANTIINFLAMMATORY AGENT;

ANAPHYLAXIS; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; BLEEDING; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG CHOICE; DRUG FATALITY; HEMOLYTIC ANEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE COUNT; CHEMICALLY INDUCED DISORDER; NOTE; RISK FACTOR; BLOOD; ECONOMICS; MIDDLE AGED;

ANTI-INFLAMMATORY AGENTS; HEMORRHAGE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; METHYLPREDNISOLONE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTORS; MIDDLE AGED; PLATELET COUNT;

EID: 0037193947     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(02)09280-2     Document Type: Letter

References (0)